Search results
AbbVie tries to reassure investors on Humira biosimilar threat
BioPharma Dive via Yahoo Finance· 2 days agoDive Brief: U.S. Humira sales fell 40% year over year during the first three months of 2024, to...
AbbVie (ABBV) Q4 2022 Earnings Call Transcript
Motley Fool· 1 year agoImage source: The Motley Fool. AbbVie (NYSE: ABBV) Q4 2022 Earnings Call Feb 09, 2023, 9:00 a.m. ET Contents: Prepared Remarks Questions and Answers Call...
AbbVie Inc (ABBV) Q1 2024 Earnings Call Transcript Highlights: Surpassing Expectations with ...
GuruFocus.com via Yahoo Finance· 1 day agoAdjusted Earnings Per Share: $2.31, $0.11 above guidance midpoint. Total Net Revenues: $12.3 billion, $400 million ahead of expectations. Ex-Humira Growth Platform Revenue Growth: Over 15% this ...
Analysts revamp AbbVie stock price target after earnings report
TheStreet via Yahoo Finance· 3 months agoAt one time, it was a was the best-selling drug on earth. The arthritis treatment Humira, approved...
Drugmaker AbbVie expects Humira volume erosion to worsen
Reuters via Yahoo News· 2 days ago(Reuters) -AbbVie expects a drop in sales volumes of its blockbuster arthritis drug Humira to deepen...
Q2 2023 Abbvie Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 9 months agoParticipants Carrie C. Strom; Senior VP of AbbVie & President of Global Allergan Aesthetics; AbbVie Inc. Elizabeth Shea; VP of IR; AbbVie Inc. Jeffrey Ryan Stewart; Executive VP & Chief Commercial ...
Is AbbVie Stock a Smart Contrarian Pick for 2023?
Motley Fool· 1 year agoImagine that someone asks you to invest in a business. This business has been highly successful in the past. However, its top-selling product accounts...
AbbVie's Recent ImmunoGen Acquisition Looks Brilliant: Here's Why
Motley Fool via Yahoo Finance· 4 months agoDrug patents don't last forever, so pharmaceutical companies are constantly looking for the next big...
AbbVie trims forecast for Humira sales drop on favorable coverage
Reuters via Yahoo Finance· 9 months ago(Reuters) -AbbVie on Thursday trimmed its 2023 view for declining sales of its flagship arthritis...
